Get Our FREE Newsletter

Sign Up

Alexion's (ALXN) PNH Drug Ultomiris Gets FDA Nod for Kids

Spread the love

Alexion Pharmaceuticals, Inc. ALXN announced that the FDA approved its long-acting C5 complement inhibitor, Ultomiris, for the treatment of children (aged one month and above) as well as adolescents with paroxysmal nocturnal hemoglobinuria (PNH), a serious ultra-rare bloo

This post was originally published on this site